Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-18

What I'm hearing is that enough trial data will be available by year end 22 to guide a strategic decision for phase 2 to proceed.
All of the operational resources and testing for Phase 1 will be left to run into 23 while preparation for phase 2 is underway.
Obviously subject to nothing going pear shaped in phase 1.
If we can get phase 2 preparation fully underway in 23 and continue phase 1 for more data until the end of 2nd qtr I'm assuming we'll pick up another $2.5m tax incentive.
This is my interpretation and not financial advice.